Shanghai Aokeda Biopharmaceutical Technology

Aokeda Biopharmaceutical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of complex generic drugs and improved new drugs via the 505(b)(2) regulatory pathway. The company focuses on high-barrier formulation technologies, including sustained-release, controlled-release, and liposomal delivery systems, to optimize the therapeutic profile of established molecules. Its primary therapeutic areas of focus are the Central Nervous System (CNS), ophthalmology, and pain management. Aokeda's lead program, OKD-007, is a bupivacaine liposome injection for postoperative pain that has reached late-stage clinical development. By leveraging its proprietary technology platforms, the company aims to address unmet medical needs and improve patient compliance through enhanced drug delivery solutions.